Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XIENCE 28 USA
NCT03815175Completed
- Sponsor
- Abbott Laboratories
- Start
- Feb 2019
- Primary completion
- Aug 2020
- Countries
- 15
01
Overview
Open-label, single-arm trial in coronary artery disease (CAD), sponsored by Abbott Laboratories. Primary endpoint: Composite Rate of All Death or All Myocardial Infarction. Started Feb 2019; status: completed.
02
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03815175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815175.